Physician profile
David Markus Diamant
NPI 1003221623
$8,982.25
in general payments reported to CMS, 2019-2025
47 companies · $1,101 in 2025
The $1,101 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $375 · 2021: $1,578 · 2022: $1,974 · 2023: $1,887 · 2024: $1,306 · 2025: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,294.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,130.53 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Pfizer INC. | $718.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $655.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $590.22 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $579.22 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $510.80 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $496.36 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $442.39 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $399.99 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2, Octrode |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.89 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.69 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $276.77 | 2019-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $247.33 | 2021-2025 | |
| Astellas Pharma US INC | $207.24 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $193.42 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Diamant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.